AbbVie (ABBV) stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.ABBV Stock Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe stock has also been consistently trading above its 50-day and 200-day moving averages since early July.The price increase in the past three months was mainly driven by AbbVie’s strong second-quarter results wherein it ...

AbbVie NYSE: ABBV is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent expiration has greatly influenced the company's future.While the "Humira cliff" is undeniably significant, a closer look reveals a company that has proactively prepared for this moment, building a diversified portfolio and strategic roadmap for continued growth. For the right investors, AbbVie presents a compelling case o ...

Core Insights - AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021, increasing from $90 to around $195, while the S&P 500 rose about 50% during the same period [1] - The significant rise in AbbVie's stock price is attributed to an 80% increase in the company's P/S ratio, which is now at 6.4x compared to 3.6x in 2020 [1] - AbbVie has experienced inconsistent stock returns, with 32% in 2021, 24% in 2022, and 0% in 2023, underperforming the S&P 500 in 2023 [2] Financial Performance - AbbVie's revenue rose 19% from $45.8 billion in 2020 to $55.0 billion in the last twelve months, largely due to the Allergan acquisition [4] - Humira, AbbVie's blockbuster drug, saw sales peak at $21.2 billion in 2022 but fell 32.2% year-over-year to $14.4 billion in 2023 due to biosimilar competition [4] - New drugs Skyrizi and Rinvoq generated $11.7 billion in 2023, reflecting a 53% year-over-year growth, while Vraylar sales increased 35% year-over-year to $2.8 billion [5] Market Position and Valuation - AbbVie is expected to deliver mid-single-digit average annual top-line growth over the next three years despite challenges with Humira [6] - The stock is currently trading at 6.3x revenues, compared to an average P/S ratio of 4.4x over the last three years, indicating it may be fully valued [3] - The average analyst price estimate for ABBV is $197, aligning with the current market price, suggesting that the stock is fully valued [6]

These stocks can help you sleep peacefully at night, even in bad times.Recessions are difficult to predict. Even professional economists sometimes get it wrong. But they will happen occasionally and sometimes take the stock market down. That's why it's useful for investors to buy shares of companies that can perform relatively well even during downturns.Which companies are worth investing in, then? Solid dividend stocks can be great picks. Their ability to maintain or even increase their payouts regardless ...

A drugmaker and a telecom business have what it takes to safely boost your passive income stream.Did you know that September is generally a lousy month for the stock market? Individual investors and hedge fund managers tend to take profits they've gained over the summer or sell off any losers to lower their taxable income.This September, the Federal Reserve is widely expected to reduce interest rates. Rate reductions tend to raise markets but investors have been expecting this one for over a year. In other ...

These businesses can stand the test of time in a diversified portfolio.Many investors are worried about a resurgence of turbulence in the markets and what that could mean for stocks in the weeks and months ahead. But great businesses can withstand the test of time and provide meaningful portfolio returns. Concerns about the U.S. economy, its impact on the global economy, and the trickle-down impact of inflation on businesses across industries are legitimate.At the same time, if you're investing your cash in ...

These three have secure core businesses, plus multiple paths to grow.Almost every portfolio needs a couple of anchor stocks that tend to grow consistently over time regardless of the mood of the market or the state of the economy. Thanks to the must-buy nature of lifesaving medicines and the regular launch of new and improved drugs, pharma stocks are a good place to look for the anchors that might be right for you.In that vein, there are three rock-solid pharma stocks in particular that are strong enough to ...

During times of market volatility, it’s always good for long-term investors to take a breath and zoom out. That doesn’t mean getting out of the markets as fast as possible. Instead, it means looking back at the past performance of the stocks they own or those on their watchlist(s).  While it’s true that you want to look for stock price growth, you also want to invest in companies that have a history of increasing revenue and earnings. This growth helps to ensure that a company can sustain a higher stock pri ...

A pharmacist assists a customer. gradyreese/iStock via Getty Images The formula for successful long-term investing is pretty simple. Quality plus a reasonable or better valuation plus time equals vigorous total returns. I've touched on what I mean by quality in past articles, but please allow me to reiterate: A track record of consistent earnings growth. If a company grows its profits just about every year, this is probably the best indicator that the business is well-run, and the business model is viable. ...

It'll be a while before there's any impact, but it could be a big deal.Eli Lilly's (LLY 0.42%) insatiable hunger to squeeze even more money out of its best-selling therapies is starting to look downright impressive. With its research and clinical groups firing on all cylinders, and management shoveling more funding into the fuel tank, the pace of its growth is more likely to accelerate than it is to slow down.And if the pharma's latest gambit pays off, it will probably start to put pressure on AbbVie (ABBV ...